



PT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Christopher L. Reading, et al.
Serial No. : 10/728,400
Filed : December 5, 2003
Title : Therapeutic Treatment Methods 2
TC/A.U. : 1614
Examiner : Brian S. Kwon

Docket No. : 202.14
Customer No. : 26,551
Confirmation No.: 9232

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed are the following papers for filing in this application:

- (X) Supplemental information disclosure statement listing 62 references, which is filed under 37 C.F.R. § 1.97(b)(3).
- (X) First class mailing certificate under 37 C.F.R. § 1.8.
- (X) Return postage prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any fees which may be required, now or in the future, or credit any overpayment to **Deposit Account No. 501536**.
- (X) Please use **Customer No. 26,551** for the correspondence address.

Date: May 20, 2006

Daryl D Muenchau

Daryl D. Muenchau
Registration No. 36,616
Attorney of Record
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-587-9333



Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY FIRST-CLASS MAIL

Serial No. : 10/728,400
Docket No. : 202.14
Applicants : Christopher L. Reading, et al.
Filed : December 5, 2003
For : Therapeutic Treatment Methods 2
Attorney : Daryl D. Muenchau, Registration No. 36,616
Date of Deposit : May 20, 2006

I hereby certify that the accompanying:

Transmittal letter; Supplemental information disclosure statement; and
Return postage prepaid postcard

are being deposited with the United States Postal Service First-Class Mail Post Office
to Addressee service under 37 CFR § 1.8 on May 20, 2006 and are addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Daryl Muenchau
Daryl Muenchau

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.
202.14APPLICATION NO.
10/728,400APPLICANT
Reading, et al.FILING DATE
December 5, 2003GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2,108,646	2-15-38	Bockmühl et al.			
	2,170,124	8-22-39	Butenandt et al.			
	2,267,257	12-23-41	Ruzcika			
	2,286,892	6-16-42	Bockmühl et al.			
	2,531,441	11-28-50	Julian et al.			
	2,561,378	7-24-51	Julian et al.			
	2,566,336	9-04-51	Julian et al.			
	2,582,258	1-15-52	Julian et al.			
	2,697,107	12-14-51	Ruschig et al.			
	2,705,238	3-29-55	Julian et al.			
	2,843,609	7-17-58	Colton			
	2,845,381	7-29-58	Tindall			
	2,878,267	3-17-59	Szpilfogel et al.			
	2,880,212	3-31-59	Grob et al.			
	2,894,958	7-14-59	Goldberg et al.			
	2,908,696	10-13-59	Nussbaum et al.			
	2,911,418	11-03-59	Johns et al.			
	2,927,119	3-01-60	Ellis et al.			
	3,001,988	9-26-61	Nysted			
	3,004,968	10-17-61	Jeger et al.			
	3,018,298	1-23-62	Klimstra et al.			
	3,060,203	10-23-62	Huffman			
	3,084,156	4-02-63	Counsell et al.			
	3,101,358	4-20-63	De Ruggieri et al.			
	3,107,254	10-15-63	Lednicer			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Reading, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE December 5, 2003	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	3,124,571	3-10-64	Ringold et al.			
	3,148,198	9-08-64	Goldcamp et al.			
	3,189,597	6-15-65	Belding et al.			
	3,189,623	6-15-65	Ayer			
	3,264,329	8-02-66	Clark et al.			
	3,281,431	10-25-66	Sollman			
	3,282,969	11-01-66	Boswell			
	3,301,872	1-31-67	Sollman			
	3,324,001	6-06-67	Bertin et al.			
	3,325,535	6-13-67	Holden et al			
	3,345,385	10-03-67	Nagata			
	3,357,888	12-12-67	Campbell et al.			
	3,380,886	4-30-68	Campbell et al.			
	3,427,300	2-11-69	Sarett et al.			
	3,436,390	4-01-69	Lefebvre et al.			
	3,673,173	6-27-72	Komeno et al.			
	3,691,207	09-12-72	Klimstra			
	3,738,983	6-12-73	Dryden et al.			
	3,780,073	12-18-73	Shroff			
	3,787,453	1-22-74	Fahrenholtz			
	3,816,480	6-11-74	Lenz			
	3,872,076	3-18-78	Rosen			
	3,917,831	11-4-75	Grunwell et al.			
	3,943,124	3-9-76	Phillipps et al.			
	3,944,576	3-16-76	van den Broek et al.			
	3,987,055	10-19-76	Berlin et al.			
	4,908,358	3-13-90	Schrieber			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 202.14	APPLICATION NO. 10/728,400
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(USE SEVERAL SHEETS IF NECESSARY)			
	APPLICANT Reading, et al.		
	FILING DATE December 5, 2003	GROUP 1614	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES)
	Antin, J., et al., Cytokine dysregulation and acute graft-versus-host disease, <i>Blood</i> , 80(12):2964-2968 1992
	Arsenou, E.S., et al., Optimization of the allylic oxidation in the synthesis of 7-keto- Δ^5 -steroidal substrates, <i>Steroids</i> , 68:407-414 2003
	Counsell, R.E., et al., Hypocholesterolemic Agents. III. N-Methyl-N-(dialkylamino)alkyl-17 β -aminoandrost-5-en-3 β -ol derivatives, <i>J. Med. Pharm. Chem.</i> , 5:1224-1233 1962
	Greinix, H., et al., Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study, <i>Blood</i> , 96(7):2426-2431 2000
	Hervé, P., et al., Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease, <i>Blood</i> , 79(12):3362-3368 1992
	Lu, M.C., et al., Inhibition of cholesterol side-chain cleavage. 4. Synthesis of A or B ring modified azacholesterols, <i>J. Med. Chem.</i> , 24:1038-1042 1981
	Martin, P.J., et al., A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment, <i>Blood</i> , 77(8):1821-1828 1991
	Ratanatharathorn, V., et al., Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease, <i>Ann Int Med</i> , 133(4):275-279 2000
	Vogelsang, G.B., How I treat chronic graft-versus-host disease, <i>Blood</i> , 97(5):1196-1201 2001
	Weisdorf, D., et al., Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome, <i>Blood</i> , 75(4):1024-1030 1990

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	